
    
      Subjects with advanced solid tumors who have no available standard therapy or who have failed
      standard therapies.

      This is an open-label, global multicenter, dose-escalation phase 1 study of safety,
      tolerability, preliminary PK profile, and preliminary efficacy of 3D185 monotherapy in
      subjects with advanced solid tumors.

      The starting dose in this dose-escalation study is 25 mg, and the preset 7 dose-escalation
      cohorts are 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg, respectively.
    
  